Simon医生问:我对DTP与b型流感杆菌（Hib）联合菌苗的效力（与这些菌苗单独应用时的效力相比较）持保留意见。Decker等证实,Hib结合菌苗接种后92％～95％产生短期免疫力（定为血清抗体至少0.15μg/ml）。Hib荚膜寡糖-CRM197突变型白喉毒素蛋白（HbOC）与Hib磷酸聚核糖基核糖醇-破伤风类毒素（PRP-T）接种后75％～83％可产生长期免疫力,抗体滴度至少1μg/ml。这些百分率表明,1％～8％的免疫儿童未产生短期保护力,17％～25％未产生长期保护力。但侵袭性Hib病例在接种儿童中极为少见。 Paradiso等发现接种DTP与HbOC联合菌苗（即TETRAMUNE）后产生的最初抗体浓 Dr. Simon asked: I have reservations about the efficacy of DTP in combination with the Hib vaccine (as compared to the potency of these vaccines when used alone). Decker et al. Demonstrated that short-term immunity (defined as serum antibody of at least 0.15 μg / ml) was produced in 92% to 95% of Hib-binding bacterins after inoculation. Long-term immunity is produced by 75% to 83% of Hib capsular oligosaccharide-CRM197 mutant diphtheria toxin protein (HbOC) and Hib phosphoribosyl-ribozan-tetanus toxoid (PRP-T) 1 μg / ml. These percentages indicate that 1% to 8% of immunized children do not have short-term protection and 17% -25% do not have long-term protection. However, aggressive Hib cases are extremely rare in vaccinated children. Paradiso et al. Found that the initial antibody concentration produced after vaccination with DTP and HbOC combined vaccine (ie, TETRAMUNE)